In Brief: MiniMed
This article was originally published in The Gray Sheet
MiniMed: Continuous subcutaneous glucose sensor 510(k) submitted to FDA, the company reports Dec. 17. MiniMed told the UBS Life Sciences conference in October that its 60-patient pivotal trial for the electrochemical-based sensor technology was in final stages and that a 510(k) for a "holter-style" glucose monitor would be submitted by year-end ("The Gray Sheet" Oct. 20, I&W-3). The company says it hopes to develop a series of products from the technology, including a hyper/hypo-glycemic alarm device, a 510(k) for which is expected to be submitted in early 1998...
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.